FidoCure To Unveil Breakthrough in Canine Hemangiosarcoma at 2024 Veterinary Cancer Society Annual Conference

PALO ALTO, Calif. (October 15, 2024) — FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings at the 2024 Veterinary Cancer Society (VCS) Annual Conference. This research, Genetic Alterations Associated with Prognosis and Better Therapeutic Outcomes in Dogs with 
Splenic Hemangiosarcoma, marks a significant advancement in the fight against hemangiosarcoma, the most prevalent and deadly cancer in dogs. This presentation highlights FidoCure’s work to connect cutting-edge science with one of the most pressing unmet needs in animal health. 

The VCS Annual Conference, scheduled for October 17-19 at the Caribe Royale Orlando, will gather top researchers, clinicians, and industry experts from around the world. With over 1,400 VCS members in attendance, this is the largest and most prestigious meeting within the veterinary oncology industry, showcasing the latest advancements in animal cancer treatment and research.

"We are honored to present our latest findings at the VCS Annual Conference," said Christina Lopes, CEO of FidoCure. "This study represents a significant leap in our understanding of canine splenic hemangiosarcoma and underscores our commitment to evidence-based medicine. As patient-centric advocates who are also pet parents, we are dedicated to continuously turning science discoveries into accessible products that positively impact the last mile of cancer care—both in the clinic and at home.”

Canine splenic hemangiosarcoma is a highly aggressive cancer that originates in the spleen and consists of abnormal blood vessels, resulting in approximately 300,000 dog deaths in the U.S. each year.

The research, led by FidoCure’s Head of Veterinary Research, Lucas Rodrigues, in collaboration with Professor James Zou, a foremost researcher in AI for canine oncology at Stanford University, involved compiling and analyzing the largest hemangiosarcoma dataset in the world, comprising millions of critical biological data points. Key findings from Genetic Alterations Associated with Prognosis and Better Therapeutic Outcomes in Dogs with Splenic Hemangiosarcoma  include:

• Enhanced survival rates for dogs treated with chemotherapy or targeted therapy compared to splenectomy alone.
• Identification of specific genetic mutations (PTEN, TP53, NRAS) linked to prognosis.
• Promising benefits of analyzing genomics to guide the use of small molecule therapies. 

"This real-world evidence bridges an important gap for the use of targeted therapies in canine splenic hemangiosarcoma," said Rodrigues. "Our findings show comparable or better outcomes than standard adjuvant chemotherapy, showcasing the power of AI-driven precision oncology for dogs facing cancer. We’re proud to partner with veterinary oncologists, providing them with cutting-edge tools and insights to enhance patient care."

FidoCure is ushering in the future of biomedical products through its global patent programs, providing beloved pets with care akin to that of their two-legged family members. While this research directly combats canine hemangiosarcoma, the findings also contribute to understanding human angiosarcoma, a rare cancer that remains an unmet need.

As FidoCure continues to advance its research, it invites pet parents and veterinarians to enroll their dogs in the FidoCure platform. Together, they can shift the narrative surrounding hemangiosarcoma from a death sentence to a beacon of hope. Every patient enrolled helps inform the care of future patients, ultimately benefiting all dogs in the fight against cancer. These insights will also enhance care for both canine companions and their human families, addressing cancer on both sides of the leash.